Oral health in oncology: impact of immunotherapy

Supportive Care in Cancer

Volumn 23, Issue 1, 2015, Pages 1-3

  Jackson, Leanne K ^a,d   Johnson, Douglas B ^a   Sosman, Jeffrey A ^a   Murphy, Barbara A ^a   Epstein, Joel B ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; MONOCLONAL ANTIBODY;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE STUDY; GRAFT VERSUS HOST REACTION; HEALTH; HUMAN; KIDNEY CARCINOMA; LETTER; METASTATIC MELANOMA; NON SMALL CELL LUNG CANCER; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; TUMOR REGRESSION; ADVERSE EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASMS; ORAL HEALTH;

EID: 84918828267     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2434-6     Document Type: Letter

References (23)

1. Hodi FS, O'Day SJ, McDermott DF (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
2. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
3. Fecher LA, Agarwala SS, Hodi FS, Weber JS (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18:733–743
4. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
5. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014.
6. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 2013.
7. Du GH, Qin XP, Li Q, Zhou YM, Shen XM, Tang GY (2011) The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells. J Oral Pathol Med 40:525–532
8. Schubert MM, Correa ME. Oral graft-versus-host disease. Dental clinics of North America 2008;52:79–109, viii-ix.
9. Deboni AL, Giordani AJ, Lopes NN (2012) Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Supportive care in cancer. Off J Multinatl Assoc Support Care Cancer 20:2903–2911
10. Pekiner FN, Demirel GY, Borahan MO, Ozbayrak S (2012) Evaluation of cytotoxic T-cell activation, chemokine receptors, and adhesion molecules in blood and serum in patients with oral lichen planus. J Oral Pathol Med 41:484–489
11. Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A (2010) Pathogenesis of oral lichen planus—a review. J Oral Pathol Med 39:729–734
12. Liu YC, Lerner UH, Teng YT. Cytokine responses against periodontal infection: protective and destructive roles. Periodontology 2000 2010;52:163–206.
13. Houshmand B, Rafiei A, Hajilooi M (2012) Influence of cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms in periodontitis. Arch Oral Biol 57:1218–1224
14. Kawai T, Eisen-Lev R, Seki M, Eastcott JW, Wilson ME, Taubman MA (2000) Requirement of B7 costimulation for Th1-mediated inflammatory bone resorption in experimental periodontal disease. J Immunol 164:2102–2109
15. Gildener-Leapman N, Ferris RL, Bauman JE (2013) Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol 49:1089–1096
16. Chambers MS, Toth BB, Martin JW, Fleming TJ, Lemon JC (1995) Oral and dental management of the cancer patient: prevention and treatment of complications. Supportive care in cancer. Off J Multinatl Assoc Support Care in Cancer 3:168–175
17. Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC (2008) Oral graft-versus-host disease. Oral Dis 14:396–412
18. Sanchez AR, Sheridan PJ, Rogers RS (2004) Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 75:613–619
19. Furness S, Bryan G, McMillan R, Worthington HV (2013) Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 8, CD009603
20. Lalla RV, Bowen J (2014) Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy, Cancer
21. Elad S, Or R, Shapira MY et al (2003) CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 32:1031–1034
22. Dijkstra PUSM, Pater R, Spijkervet FKL, Roodenburg JLN (2007) Exercise therapy for trismus in head and neck cancer. Oral Oncol 43:389–394
23. Coracin FL, Pizzigatti Correa ME, Camargo EE et al (2006) Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. Bone Marrow Transplant 37:955–959